{
  "id": 9584583,
  "title": "Here's Why Viking Therapeutics Shares Slumped Today",
  "url": "https://urgent.news/2026/09/24/heres-why-viking-therapeutics-shares-slumped-today-9584583",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-24T15:30:33.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/24/heres-why-viking-therapeutics-shares-slumped-today/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Viking Therapeutics (NASDAQ: VKTX) shares experienced a significant drop of 14.5% in early trading on Monday, following the company's announcement of the results from a maintenance study of its key weight-loss drug, VK2735. Despite the initial decline, the results were promising and led management to announce a new offering of common stock and convertible senior notes. The company raised an additional $200 million through the sale of these securities, which were initially priced at $35 per share and $225 million in convertible senior notes due in 2023. The increased offering was met with positive market response, prompting Viking Therapeutics to expand the offering to 7,857,143 shares at $35 each and $225 million in convertible senior notes. It is important to note that today's share price decline is not directly linked to the positive results released two days ago.",
  "summary": "It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Here's Why Viking Therapeutics Shares Slumped Today",
        "url": "https://urgent.news/2026/09/24/heres-why-viking-therapeutics-shares-slumped-today",
        "published": "2026-09-24T15:50:33.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}